Jane Street
SPRY icon

Jane Street’s ARS Pharmaceuticals SPRY Stock Holding History

Jane Street’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-242,037
Closed -$2.35M – 12307
2025
Q3 		$2.43M Buy
+242,037
New +$3.47M ﹤0.01% 4577
2025
Q1 		– Sell
-21,154
Closed -$255K – 10543
2024
Q4 		$223K Sell
21,154
-67,583
-76% -$947K ﹤0.01% 8227
2024
Q3 		$1.29M Sell
88,737
-25,637
-22% -$305K ﹤0.01% 5368
2024
Q2 		$973K Buy
114,374
+22,046
+24% +$196K ﹤0.01% 5825
2024
Q1 		$944K Buy
92,328
+4,163
+5% +$31K ﹤0.01% 5526
2023
Q4 		$483K Buy
88,165
+66,713
+311% +$292K ﹤0.01% 6817
2023
Q3 		$81.1K Sell
21,452
-4,391
-17% -$28.8K ﹤0.01% 8033
2023
Q2 		$173K Sell
25,843
-111,607
-81% -$745K ﹤0.01% 7739
2023
Q1 		$895K Buy
137,450
+117,793
+599% +$905K ﹤0.01% 5212
2022
Q4 		$168K Buy
19,657
+5,474
+39% +$35.5K ﹤0.01% 7792
2022
Q3 		$75K Buy
+14,183
New +$69.9K ﹤0.01% 8771
2021
Q3 		– Sell
-9,111
Closed -$281K – 10678
2021
Q2 		$281K Buy
+9,111
New +$292K ﹤0.01% 8262
2021
Q1 		– Sell
-19,038
Closed -$882K – 9559
2020
Q4 		$882K Buy
+19,038
New +$636K ﹤0.01% 4865

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jane Street's SPRY Position: Q4 2025 in Review

Jane Street sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 242,037 shares — an estimated $2.35M sold.

Jane Street first reported a position in SPRY in Q4 2020 and held it in 13 quarters. The position peaked at $2.43M in Q3 2025. 189 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Jane Street reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Jane Street sold 242,037 ARS Pharmaceuticals shares in Q4 2025, an estimated $2.35M.
  • Jane Street first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 13 quarters.
  • Jane Street's ARS Pharmaceuticals position peaked at $2.43M in Q3 2025.
  • 189 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.